{
    "Clinical Trial ID": "NCT00263588",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cohort A",
        "  750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings",
        "INTERVENTION 2: ",
        "  Cohort B",
        "  750mg lapatinib administered orally twice daily. Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings."
    ],
    "Eligibility": [
        "Inclusion criteria:",
        "  Signed Informed Consent",
        "  ErbB2(HER2)overexpressing breast cancer.",
        "  Brain lesion(s) which are progressing.",
        "  Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS).",
        "  Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy.",
        "  Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram.",
        "  Able to swallow an oral medication.",
        "  Adequate kidney and liver function.",
        "  Adequate bone marrow function.",
        "Exclusion criteria:",
        "  Pregnant or lactating females.",
        "  Conditions that would effect the absorption of an oral drug.",
        "  History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.",
        "  Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.",
        "  Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Number of Participants With Central Nervous System (CNS) Best Overall Response",
        "  Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population)",
        "  Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.",
        "  The primary indicator of drug efficacy was CNS objective response rate. A CNS objective response was defined as either a Complete response (CR) or Partial response (PR), as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of Neurological signs and symptoms (NSS)",
        "  A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions, with no new or progressive CNS or non-CNS lesions, no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms",
        "  Time frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years",
        "Results 1: ",
        "  Arm/Group Title: Cohort A",
        "  Arm/Group Description: 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings",
        "  Overall Number of Participants Analyzed: 94",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Complete response (CR): 0   0.0%",
        "  Partial response (PR): 6   6.4%",
        "  Stable disease (SD): 40  42.6%",
        "  Progressive disease (PD): 40  42.6%",
        "Unknown: 8   8.5%",
        "Results 2: ",
        "  Arm/Group Title: Cohort B",
        "  Arm/Group Description: 750mg lapatinib administered orally twice daily. Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings.",
        "  Overall Number of Participants Analyzed: 143",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Complete response (CR): 0   0.0%",
        "  Partial response (PR): 9   6.3%",
        "  Stable disease (SD): 46  32.2%",
        "  Progressive disease (PD): 70  49.0%",
        "  Unknown: 18  12.6%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 36/95 (37.89%)",
        "  Atrial fibrillation 0/95 (0.00%)",
        "  Cardio-respiratory arrest 1/95 (1.05%)",
        "  Left ventricular dysfunction 0/95 (0.00%)",
        "  Pericardial effusion 0/95 (0.00%)",
        "  Vertigo 0/95 (0.00%)",
        "  Constipation 1/95 (1.05%)",
        "  Diarrhoea 6/95 (6.32%)",
        "  Duodenal ulcer 0/95 (0.00%)",
        "  Duodenal ulcer haemorrhage 0/95 (0.00%)",
        "  Gastrointestinal haemorrhage 0/95 (0.00%)",
        "Adverse Events 2:",
        "  Total: 52/147 (35.37%)",
        "  Atrial fibrillation 1/147 (0.68%)",
        "  Cardio-respiratory arrest 0/147 (0.00%)",
        "  Left ventricular dysfunction 1/147 (0.68%)",
        "  Pericardial effusion 1/147 (0.68%)",
        "  Vertigo 1/147 (0.68%)",
        "  Constipation 0/147 (0.00%)",
        "  Diarrhoea 4/147 (2.72%)",
        "  Duodenal ulcer 1/147 (0.68%)",
        "  Duodenal ulcer haemorrhage 1/147 (0.68%)",
        "  Gastrointestinal haemorrhage 2/147 (1.36%)"
    ]
}